-

Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors

BILBAO, Spain--(BUSINESS WIRE)--After 15 years of pioneering R&D efforts in the tumor microenvironment, Oncomatryx announces that the FDA and the Spanish Drug Agency (AEMPS) have cleared its investigational new drug (IND) application for OMTX705, a First-in-Class antibody-drug conjugate (ADC) targeting the tumor microenvironment.

OMTX705 is a pioneering ADC that targets, with a novel, dual mechanism of action, the Cancer-Associated Fibroblasts that enable tumor metastasis, drug resistance and immunosuppression.

OMTX705 has already shown unbeatable safety in non-human primates and tumor regression in murine models of pancreatic, breast, lung and gastric cancer.

Oncomatryx will run a multicenter, dose escalation trial in patients suffering metastatic solid tumors. OMTX705 will be administered as single agent and in combination with immunotherapy.

OMTX705 phase I clinical trial will be run in seven hospitals in USA and Spain.

About Oncomatryx

Oncomatryx, a global biopharmaceutical company, is pioneering the development of precision ADCs and bispecific antibodies against novel targets in the tumor microenvironment.

The company, located in the Bizkaia Technology Park (Bilbao, Spain), has discovered novel pathways and proteins in the Cancer-Associated Fibroblasts that surround the tumor and promote its invasiveness, immunosuppression and drug resistance.

Oncomatryx has undertaken the development of pioneering drugs against these pathways and proteins of the tumor microenvironment, in collaboration with prestigious universities and hospitals in USA and Europe, led by the Institute of Cell Biology and Immunology of the University of Stuttgart (Germany).

Oncomatryx is investing 50 million euros in 2022-2024, to develop OMTX705 and other novel tumor microenvironment-targeted ADCs and Bispecific antibodies.

www.oncomatryx.com

Contacts

Pedro Esnaola
admin@oncomatryx.com
+34 946 087 037

Industry:

Oncomatryx

Release Versions
English

Contacts

Pedro Esnaola
admin@oncomatryx.com
+34 946 087 037

More News From Oncomatryx

Oncomatryx Biopharma Awarded €12.5 Million EIC Accelerator Funding to Advance Groundbreaking ADCs

BILBAO, Spain--(BUSINESS WIRE)--Oncomatryx Biopharma, a biotechnology company pioneering next-generation Antibody-Drug Conjugates (ADCs) for oncology, has been awarded funding from the European Innovation Council (EIC) Accelerator under the EU’s Horizon Europe 2021-2027 Research and Innovation Program. As part of this highly competitive program, Oncomatryx will receive €2.5 million in grant funding, along with a €10 million equity investment in its upcoming financing round. The EIC Accelerator...

ONCOMATRYX Raises €25 Million to Foster OMTX705 Clinical Trials

ZAMUDIO, Spain--(BUSINESS WIRE)--ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund Phase Ib-II clinical trials of OMTX705, a first-in-class ADC targeting FAP. The funding round was led by the company’s existing investors and included a €10 million strategic investment from Centro para el Desarrollo Tecnológico y la Innovación. This endorsement highlights the confidence in ONCOMATRYX pioneering ADCs to t...

Oncomatryx acquires Tube Pharmaceuticals GmbH to consolidate its pioneering pipeline of ADCs targeting the tumor microenvironment

ZAMUDIO, Spain--(BUSINESS WIRE)--Oncomatryx has acquired Tube Pharmaceuticals GmbH, the developer of the Cytolysin toxic payload. The multimillion €uros transaction is a strategic decision by Oncomatryx that will foster its leadership in the field of ADCs targeting the tumor microenvironment. It culminates a decade-long alliance between Oncomatryx and Tube that has already rendered clinical-stage ADCs targeting the Tumor Microenvironment. Oncomatryx's pioneering drug OMTX705, which incorporates...
Back to Newsroom